Literature DB >> 19854435

The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb/c and C57Bl/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers.

Deijanira Albuquerque1, Jorge Nihei, Fabíola Cardillo, Ram Singh.   

Abstract

Increasing evidence implies beneficial effects of angiotensin-converting enzyme (ACE) inhibitors beyond those of their original indications to control hypertension. One of the most attractive non-hemodynamic properties of ACE inhibitors is their ability to regulate cytokine production. The mechanism(s) underlying the role of ACE inhibitors on cytokine synthesis are not well understood but they have traditionally been attributed to the inhibition of angiotensin (Ang) II formation. In fact, it has been extensively demonstrated that ACE inhibitors decrease Ang II-induced production of proinflammatory cytokines and chemokines. However, it is not well described if inhibition of endogenous Ang II generation by ACE inhibitors modulates systemic cytokine production in mice. To verify that, in this work, we investigated the effects of treatment with the ACE inhibitors enalapril and captopril on cytokine synthesis in C57Bl/6 and Balb/c mice. Our results show that enalapril up regulates IL-10 produced by splenocytes from Balb/c and C57Bl/6 mice and captopril increased it only in Balb/c mice. Furthermore, CD4(+)CD103(+) presented increased IL-10 production after enalapril treatment. Enalapril as well as captopril short-term treatment enhanced IL-2 synthesis in Balb/c mice. Besides, enhanced IL-2 and IL-10 levels correlates with increased CD4(+)CD103(+)CD25(negative) T cells numbers in spleens from enalapril-treated mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19854435     DOI: 10.1016/j.cellimm.2009.09.006

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  14 in total

1.  Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonist attenuate tumor growth via polarization of neutrophils toward an antitumor phenotype.

Authors:  Sanjeeb Shrestha; Jae Myoung Noh; Shin-Yeong Kim; Hwa-Yong Ham; Yeon-Ja Kim; Young-Jin Yun; Min-Ju Kim; Min-Soo Kwon; Dong-Keun Song; Chang-Won Hong
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

2.  Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB.

Authors:  José L Miguel-Carrasco; Sonia Zambrano; Antonio J Blanca; Alfonso Mate; Carmen M Vázquez
Journal:  J Inflamm (Lond)       Date:  2010-05-12       Impact factor: 4.981

Review 3.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

4.  Enhancement of anti-OVA IgG2c production in vivo by enalapril.

Authors:  L C Almeida; L S Muraro; D A Albuquerque
Journal:  Braz J Med Biol Res       Date:  2016-07-11       Impact factor: 2.590

5.  Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.

Authors:  Zahra Sepehri; Mohammad Masoumi; Nazanin Ebrahimi; Zohre Kiani; Ali Akbar Nasiri; Farhad Kohan; Mahmood Sheikh Fathollahi; Mohammad Kazemi Arababadi; Gholamreza Asadikaram
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

6.  The chronic blockade of angiotensin I-converting enzyme eliminates the sex differences of serum cytokine levels of spontaneously hypertensive rats.

Authors:  P L M Dalpiaz; A Z Lamas; I F Caliman; A R S Medeiros; G R Abreu; M R Moysés; T U Andrade; M F Alves; A K Carmona; N S Bissoli
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

7.  Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.

Authors:  Alecia Seliga; Michael Hweemoon Lee; Nicole C Fernandes; Viviana Zuluaga-Ramirez; Marta Didukh; Yuri Persidsky; Raghava Potula; Stefania Gallucci; Uma Sriram
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

Review 8.  Drug repurposing and cytokine management in response to COVID-19: A review.

Authors:  Luana Heimfarth; Mairim Russo Serafini; Paulo Ricardo Martins-Filho; Jullyana de Souza Siqueira Quintans; Lucindo José Quintans-Júnior
Journal:  Int Immunopharmacol       Date:  2020-08-31       Impact factor: 4.932

9.  Centrally Acting Angiotensin-Converting Enzyme Inhibitor Suppresses Type I Interferon Responses and Decreases Inflammation in the Periphery and the CNS in Lupus-Prone Mice.

Authors:  Cassandra Nocito; Cody Lubinsky; Michelle Hand; Sabeeya Khan; Tulsi Patel; Alecia Seliga; Malika Winfield; Viviana Zuluaga-Ramirez; Nicole Fernandes; Xiangdang Shi; Ellen M Unterwald; Yuri Persidsky; Uma Sriram
Journal:  Front Immunol       Date:  2020-09-15       Impact factor: 7.561

10.  Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN-γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients.

Authors:  Pablo R G Cardoso; Katherine A Matias; Andrea T Dantas; Claudia D L Marques; Michelly C Pereira; Angela L B P Duarte; Moacyr Jesus Barreto de Melo Rego; Ivan da Rocha Pitta; Maira Galdino da Rocha Pitta
Journal:  Open Rheumatol J       Date:  2018-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.